Roopal Vashi Kundu

Roopal Vashi Kundu

Auto-generated profile, based on publicly available information

Roopal Vashi Kundu

Northwestern University Feinberg School of Medicine, Chicago, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
LWLaura A. Walsh
Laura A. Walsh
EWEllen Wu
Ellen Wu
DPDavid Pontes
David Pontes
KKKevin R. Kwan
Kevin R. Kwan
SPSneha Poondru
Sneha Poondru
RKRoopal V. Kundu
Roopal V. Kundu
Background: Keloids are pathologic scars that pose a significant functional and cosmetic burden. They are challenging to treat, despite the multitude of treatment modalities currently available. Objective: The aim of this study was to conduct an evidence-based review of all prospective data regarding keloid treatments published between 2010 and 2020. Methods: A systematic literature search of PubMed (National Library of Medicine), Embase (Elsevier), and Cochrane Library (Wiley) was performed in November of 2020. Search strategies with the keywords “keloid” and “treatment” were performed by a medical librarian. The search was limited to prospective studies that were peer-reviewed, reported on clinical outcomes of keloid therapies, and were published in the English language between January 1, 2010, and November 24, 2020. Results: A total of 3462 unique citations were identified, of which 108 studies met inclusion criteria. Current literature supports silicone gel or sheeting with corticosteroid injections as first-line therapy for keloids. Adjuvant intralesional 5-fluorouracil (5-FU), bleomycin, or verapamil can be considered, although mixed results have been reported with each. Laser therapy can be used in combination with intralesional corticosteroids or topical steroids with occlusion to improve drug penetration. Excision of keloids with immediate post-excision radiation therapy is an effective option for recalcitrant lesions. Finally, silicone sheeting and pressure therapy have evidence for reducing keloid recurrence. Conclusions: This review was limited by heterogeneity of subject characteristics and study outcome measures, small sample sizes, and inconsistent study designs. Larger and more robust controlled studies are necessary to further understand the variety of existing and emerging keloid treatments, including corticosteroids, cryotherapy, intralesional injections, lasers, photodynamic therapy, excision and radiation, pressure dressings, and others.

20 February 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
CTCristina Thomas
Cristina Thomas
SNSaravu R Narahari
Saravu R Narahari
KBKuthaje S Bose
Kuthaje S Bose
KVKuthaje Vivekananda
Kuthaje Vivekananda
SNSteven Nwe
Steven Nwe
RKRoopal V Kundu
Roopal V Kundu
The Global Program to Eliminate Lymphatic Filariasis aims to interrupt transmission of lymphatic filariasis and manage morbidity in people currently living with the disease. A component of morbidity management is improving health-related quality of life (HRQoL) in patients. Measurement of HRQoL in current management programs is varied because of the lack of a standard HRQoL tool for use in the lymphatic filariasis population. In this study, the psychometric properties of three health status measures were compared when used in a group of lymphatic filariasis patients and healthy controls. The World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), the Dermatology Life Quality Index (DLQI), and the Lymphatic Filariasis Quality of Life Questionnaire (LFSQQ) were administered to 36 stage II and stage III lymphatic filariasis subjects and 36 age and sex matched controls in Kerala, India. All three tools yielded missing value rates lower than 10%, suggesting high feasibility. Highest internal consistency was seen in the LFSQQ (α = 0.97). Discriminant validity analysis demonstrated that HRQoL was significantly lower in the LF group than in controls for the WHODAS 2.0, DLQI, and LFSQQ, but total HRQoL scores did not differ between stage II and stage III lymphedema subjects. The LFSQQ total score correlated most strongly with the WHODAS 2.0 (r = 0.91, p<0.001) and DLQI (r = 0.81, p<0.001). The WHODAS 2.0, DLQI, and LFSQQ demonstrate acceptable feasibility, internal consistency, discriminate validity, and construct validity. Based on our psychometric analyses, the LFSQQ performs the best and is recommended for use in the lymphatic filariasis population. Lymphatic filariasis affects approximately 120 million people and is the second leading cause of life-long disability worldwide. Because lymphatic filariasis is one of the World Health Organization's six eradicable diseases, much effort has been placed into reducing transmission of the disease and managing morbidity. Novel interventions frequently use health-related quality of life as an outcome measure to monitor efficacy of the intervention. In an effort to delineate the strengths and weaknesses of health status measures and recommend use of a single tool in the lymphatic filariasis population, we compared the use of three health status tools (The World Health Organization Disability Assessment Schedule 2.0, the Dermatology Life Quality Index, and the Lymphatic Filariasis Quality of Life Questionnaire) in lymphatic filariasis subjects and healthy controls in Kerala, India. The Lymphatic Filariasis Quality of Life Questionnaire performed the best by discriminating well between subjects and controls, possessing significant content overlap with the other two tools, yielding a low missing value rate, and being internally consistent. This is the first study to compare health status measures in lymphatic filariasis subjects and provides insight into the use of the tools in quality of life analysis.

1 April 2009 in Dermatologic Surgery
Verified
Journal Article
Closed access
PDF file
SJSmita S. Joshi
Smita S. Joshi
SBSusan L. Boone
Susan L. Boone
MAMurad Alam
Murad Alam
SYSimon Yoo
Simon Yoo
LWLucile White
Lucile White
RKRoopal V. Kundu
Roopal V. Kundu

13 May 2014 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
PMPamela Madu
Pamela Madu
RKRoopal V. Kundu
Roopal V. Kundu

1 May 2010 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
RKRoopal V. Kundu
Roopal V. Kundu
MKMonique Kamaria
Monique Kamaria
SOSara Ortiz
Sara Ortiz
DWDennis P. West
Dennis P. West
ARAlfred W. Rademaker
Alfred W. Rademaker
JRJune K. Robinson
June K. Robinson

9 December 2016 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
NVNeelam A. Vashi
Neelam A. Vashi
SWStephen A. Wirya
Stephen A. Wirya
MIMeyene Inyang
Meyene Inyang
RKRoopal V. Kundu
Roopal V. Kundu